Reaction

Angiolymphoid Hyperplasia With Eosinophilia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 34 reports · 1 co-occurring drugs

As of the last recalculation, Angiolymphoid Hyperplasia With Eosinophilia appears in 34 FAERS reports alongside 1 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB CITRATE (PRR 758.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Tofacitinib Citrate11758.8759.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.